Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a phase 2 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

NLNicole R. LeBoeufAEAshleigh Eberly-Puleo

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows TAG-AZA-VEN treatment improves progression-free survival and tolerability in patients with BPDCN, suggesting effective transplant potential.

Key Points

  • Triplet therapy results in improved progression-free survival in patients with BPDCN, presenting a new treatment option.
  • In the cohort receiving first-line treatment, 88% achieved composite CR, while 64% responded in the relapsed/refractory group.
  • Observational analysis across patients showed manageable treatment-related adverse events, with key concerns being neutropenia and capillary leak syndrome.
  • The findings suggest a feasible approach for older BPDCN patients to proceed to transplant while maintaining safety.

Cite This Study

LeBoeuf et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d402https://doi.org/10.1182/blood-2025-653
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Longer survival with tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Results of a real-world analysis2025 · 1 citations
  2. 2Tagraxofusp and low-intensity chemotherapy for the treatment of CD123-positive relapsed or refractory Acute Myeloid Leukemia2025
  3. 3Real-world use of venetoclax and hypomethylating agents (HMA) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): A multi-institutional case series2025 · 1 citations
  4. 4Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed (ND) FLT3mut+ Acute Myeloid Leukemia (AML) ineligible for intensive induction chemotherapy (chemo): Interim results from the phase 1/2 VICEROY study2025 · 11 citations
  5. 5Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome2025 · 2 citations